Skip to content skip to primary navi skip to secondary navi skip to meta navi search

Publikationen 2013

Originalarbeiten

  • Behringer K, Müller H, Görgen, H, Thielen I, Eibl A, Stumpf V, Wessels C, Wiehlpütz M, Rosenbrock J, Halbsguth T, Reiners KS, Schober T, Renno JH, von Wolff M, van der Ven K, Kuehr M, Fuchs M, Diehl V, Engert E, Borchmann P on behalf of the German Hodgkin Study Group. Gonadal function and fertility in survivors after Hodgkin Lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol Jan 10;31(2):231-9 (2013)
  • Sauer M, Plütschow A, Jachimowicz R, Kleefisch D, Reiners KS, Ponader S, Engert A, Pogge von Strandmann E. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol Feb;88(2):113-5 (2013)
  • Sasse S, Rothe A, Goergen H, Eichenauer DA, Lohri A, Kreher S, Jäger U, Bangard C, Kuhnert G, Böll B, von Tresckow B, Engert A. Brentuximab Vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin Lymphoma. Leuk Lymphoma Feb 13 (2013) [Epub ahead of print]
  • Schoof N, Franklin J, Fürst R, Zander T, von Bonin F, Peyrade F, Trümper L, Diehl V, Engert A, Kube D, Re D. Interleukin-10 gene polymorphisms are associated with freedom from treatment failure in Hodgkin Lymphoma patients. Oncologist 18(1):80-9 (2013)
  • Theurich S, Malcher J, Wennhold K, Shimabukuro-Vornhagen A, Chemnitz J, Holtick U, Krause A, Kobe C, Kahraman D, Engert A, Scheid C, Chakupurakal G, Hallek M, von Bergwelt-Baildon M. Brentuximab Vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma following allogeneic stem cell transplantation induces tumor specific immunity and sustained clinical remission. Diagnosis in Oncology. J Clin Oncol Feb 10;31(5):e59-63 (2013)
  • Böll B, Görgen H, Fuchs M, Plütschow A, Eich HT, Bargetzi MJ, Weidmann E, Junghanß C, Greil R, Scherpe A, Schmalz O, Eichenauer DA, von Tresckow B, Rothe A, Diehl V, Engert A, Borchmann P. ABVD in older patients with early-stage Hodgkin Lymphoma treated within the German Hodgkin Study Group (GHSG) HD10 and HD11 trials. J Clin Oncol Apr 20;31(12):1522-9 (2013)
  • Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, Reusch U, Hucke C, Köhl U, Dürkop H, Engert A, Pogge von Strandmann E. Rescue of impaired NK cell activity in Hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther 21(4):895-903 (2013)
  • Ouyang J, Plütschow A, Pogge von Strandmann E, Reiners KS, Ponader S, Rabinovich GA, Neuberg D, Engert A, Shipp MA. Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. Blood Apr 25;121(17):3431-3 (2013)
  • Arai S, Fanale M, deVos S, Engert A, Illidge T, Borchmann P, Younes A, Morschhauser F, McMillan A, Horning S. Defining a Hodgkin Lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplantation. Letter to the editor. Leuk Lymphoma April 26 (2013) [Epub ahead of print]
  • Han TH, Chen R, Advani R, Berryman RB, Smith SE, Forero-Torres A, Rosenblatt JD, Smith MR, Zain J, Hunder N, Engert A. Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies. Cancer Chemotherapy and Pharmacology May 30 (2013) [Epub ahead of print]
  • Von Tresckow B, Böll B, Eichenauer D, Peine D, Knop S, Göbeler ME, Chemnitz J, Hallek M, Engert A, Hübel K. Anti-EGFR antibody cetuximab in refractory or relapsed multiple myloma: A phase II prospective clinical trial. Leuk Lymphoma May 29 (2013) [Epub ahead of print]
  • Sauer M, Reiners KS, Hansen HP, Engert A, Gasser S, Pogge von Strandmann E. Induction of the DNA damage response by IAP inhibition triggers natural immunity via upregulation of NKG2D ligands in Hodgkin lymphoma in vitro. Biol Chem June 20 (2013) [Epub ahead of print]
  • Borchmann P, Kreissl S, Diehl V, Engert A. Treatment of advance stage Hodgkin Lymphoma: let’s face the facts. Letter to the editor. J Clin Oncol July 8 (2013) [Epub ahead of print]
  • Wongso D, Fuchs M, Plütschow A, Klimm B, Sasse S, Hertenstein B, Maschmeyer G, Vieler T, Dührsen U, Lindemann W, Aulitzky W, Diehl V, Borchmann P, Engert A. Treatment-related mortality in patients with advanced-stage Hodgkin lymphoma: An analysis of the German Hodgkin Study Group (GHSG). J Clin Oncol June 24 (2013) [Epub ahead of print]
  • Harrison SJ, Hsu A, Neeson P, Younes A, Sureda A, Engert A, Prince HM, Li M, Savage P, Bugarini R, Williams D, Squier M, Ritchie D. Early TARC reduction and response following Panobinostat treatment in patients with relapsed/refractory Hodgkin’s lymphoma following autologous stem cell transplant. Leuk Lymphoma July 4 (2013) [Epub ahead of print]
  • Skoetz N, Trelle S, Rancea M, Haverkamp H, Diehl V, Engert A, Borchmann P. Survival of advanced stage Hodgkin lymphoma patients after different initial treatment strategies: a systematic review and network meta-analysis. Lancet Oncol (accepted)
  • Klein JM, Henke A, Sauer M, Bessler M, Reiners KS, Engert A, Hansen HP, von Strandmann EP. The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines. PLoS One. 2013 Nov 21;8(11):e79502.
  • Böll B, Goergen H, Arndt N, Meissner J, Krause SW, Schnell R, von Tresckow B, Eichenauer DA, Sasse S, Fuchs M, Behringer K, Klimm BC, Naumann R, Diehl V, Engert A, Borchmann P. Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study group. J Clin Oncol. 2013 Dec 10;31(35):4431-7.
  • Frampton M, da Silva Filho MI, Broderick P, Thomsen H, Försti A, Vijayakrishnan J, Cooke R, Enciso-Mora V, Hoffmann P, Nöthen MM, Lloyd A, Holroyd A, Eisele L, Jöckel KH, Ponader S, von Strandmann EP, Lightfoot T, Roman E, Lake A, Montgomery D, Jarrett RF, Swerdlow AJ, Engert A, Hemminki K, Houlston RS. Variation at 3p24.1 and 6q23.3 influences the risk of Hodgkin's lymphoma. Nat Commun. 2013;4:2549.
  • Hartmann S, Eichenauer DA, Plütschow A, Mottok A, Bob R, Koch K, Bernd HW, Cogliatti S, Hummel M, Feller AC, Ott G, Möller P, Rosenwald A, Stein H, Hansmann ML, Engert A, Klapper W. The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood. 2013 Dec 19;122(26):4246-52; quiz 4292.

Übersichtsarbeiten

  • Rancea M, Engert A, von Tresckow B, Halbsguth T, Behringer K, Skoetz N. Hodgkin- Lymphom beim erwachsenen Patienten (Hodgkin’s Lymphoma in Adults). Klinische Leitlinie (Clinical Practice Guideline). Diagnostik, Therapie und Nachsorge (Diagnosis, Treatment and Follow-up). Dtsch Arztebl Int Mar;110(11):177-83 (2013)
  • Eich HT, Kriz J, Schmidberger H, Böll B, Klimm B, Rancea M, Müller RP, Engert A. The German Evidence Based-Guideline Hodgkin’s Lymphoma. Aspects for Radiation Oncologists. Strahlenther Onkol 6;189:445-447 (2013)
  • Skoetz N, Engert A. Interdisziplinäre S-3 Leitlinie zur Diagnostik, Therapie und Nachsorge des Hodgkin Lymphoms bei erwachsenen Patienten. Leitlinienprogramm Onkologie. DGHO Leitlinie. Februar (2013)
  • Eichenauer D, Engert A. VII. Management of nodular lymphocyte-predominant Hodgkin lymphoma. Hematol Oncol 31(Suppl.I):47-50 (2013)
  • Dietlein M, Kuhnert G, Kahraman D, Engert A, Borchmann P, Fuchs M, Baues C, Eich H, Drzezga A, Kobe C. Early interim PET/CT beim Hodgkin Lymphom des Erwachsenen - Von der Risikostratifizierung zur Therapiestratifiierung. Der Nuklearmediziner 36:79-85 (2013)
  • von Tresckow B, Engert A. Refractory Hodgkin lymphoma. Curr Opin Oncol. 2013 Sep;25(5):463-9.
  • Engert A. 25. CD30-positive malignant lymphomas: time for a change of management? Haematologica. 2013 Aug;98(8):1165-8.
  • Rancea M, Will A, Borchmann P, Monsef I, Engert A, Skoetz N. Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma. J Natl Cancer Inst. 2013 Aug 7;105(15):1159-70.
  • Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma. Cochrane Database Syst Rev. 2013 Jun 20;6:CD009411.